Staying Ahead of the Curve with Sensitivity and Specificity

Novel Psychoactive Substances (NPS) are new drugs that have been designed specifically to circumvent existing laws regarding drug control and scheduling guidelines. Beginning in 2008 with synthetic cannabinoids, the category now includes hundreds of novel benzodiazepines, stimulants, hallucinogens, and most importantly opioids including fentanyl analogues. These are the substances that are responsible for contributing to the exponential increase in deaths and addiction represented by the growing opioid crisis.

NMS Labs offers a comprehensive test portfolio for Novel Psychoactive Substances to support medical examiners, coroners, law enforcement agencies, Drug Recognition Experts (DREs), crime laboratories, and healthcare providers. Extensive market intelligence allows NMS Labs to regularly update our scope of NPS Screens ensuring detection using the most current and relevant tests.

NPS Portfolio

NPS Portfolio


There is little published research for NPS because of the short life span in the online market. Older drug screens will not detect emerging NPS compounds and analogues. A test that worked a year ago will not be picking up today’s priority compounds. These drugs have become the most challenging aspect of toxicology testing. Our NPS Portfolio contains supplementary drug panels that can save time to identification as well as costs associated with testing beyond the standard drug panel.

Extensive market surveillance allows NMS Labs to stay ahead of the curve, and regularly update the scope of its NPS Screens and Designer Opioid Panels, increasing the likelihood of detection using the most current and relevant technologies.


Fentanyl Analogues in Blood Screened by TOF